SCHEMBL5550833

SCHEMBL5550833

CCOC(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICAM1 P05362 6/20 0.70
SELE P16581 6/20 0.70
GSK3A P49840 11/20 0.66
PIM1 P11309 10/20 0.66
GSK3B P49841 10/20 0.66
DYRK1A Q13627 10/20 0.66
CDK5 Q00535 9/20 0.66
CDK2 P24941 9/20 0.66
CSNK1D P48730 9/20 0.66
KDR P35968 8/20 0.66
LIMK1 P53667 8/20 0.66
CHEK2 O96017 8/20 0.66
MAPK9 P45984 8/20 0.66
PLK4 O00444 7/20 0.66
SGK2 Q9HBY8 7/20 0.66
AURKA O14965 7/20 0.66
CSNK2A1 P68400 6/20 0.66
ROCK1 Q13464 6/20 0.66
MAPK8 P45983 6/20 0.66
PRKD2 Q9BZL6 6/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19769141 0.84 PIM1 (0.69) ICAM1SELEGSK3APIM1GSK3B
SCHEMBL7055220 0.83 ICAM1 (1.00) ICAM1SELEGSK3APIM1GSK3B
SCHEMBL5550778 0.82 PIM1 (0.78) ICAM1SELEGSK3APIM1GSK3B
SCHEMBL19769135 0.80 PIM1 (0.71) ICAM1SELEGSK3APIM1GSK3B
SCHEMBL7057206 0.80 ICAM1 (0.64) ICAM1SELEGSK3APIM1GSK3B
SCHEMBL5555786 0.80 PIM1 (0.78) ICAM1SELEGSK3APIM1GSK3B
SCHEMBL7055380 0.78 PIM1 (1.00) ICAM1SELEGSK3APIM1GSK3B
SCHEMBL7055360 0.78 PIM1 (0.76) ICAM1SELEGSK3APIM1GSK3B
SCHEMBL7050653 0.78 GSK3A (1.00) ICAM1SELEGSK3APIM1GSK3B
SCHEMBL7056743 0.78 GSK3A (1.00) ICAM1SELEGSK3APIM1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 ICAM1 4375/4885SELE 4256/4885GSK3A 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.